Acorda Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Therapeutics (ACOR) Tops Q1 EPS by 1c
April 30, 2015 6:06 AM EDTAcorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $99.85 million versus the consensus estimate of $100.2 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
... More